L-Bupivacaine
Chronic Pain Syndrome
Tanta UniversitySmall moleculePhase 4 / ApprovedActive
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 73/ 100
Competitive context
90 Active assets in the Chronic Pain Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-Tramadol EMS | Phase 4 | BBB |
Lidocaine National and Kapodistrian University of Athens | Phase 4 | BBB |
Methadone Cari Health Inc. | Phase 4 | BBB |
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Stanford University | Phase 4 | BBB |
Fentanyl Aga Khan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
L-Bupivacaine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →